We identified AZA1 as a novel Rac and Cdc42 inactivating compound with significantly improved inhibition of Rac combined with additional Cdc42 inhibitory activity when used in EGF-stimulated 22Rv1 prostate cancer cells. This evidence concerns the gene AKT1 and prostate cancer.